Valuation: Protara Therapeutics, Inc.

Market Cap 160M 142M 132M 121M 227M 15.34B 230M 1.6B 620M 7.84B 599M 586M 25.17B P/E 2026 *
-1.95x
P/E 2027 * -1.76x
Enterprise Value 160M 142M 132M 121M 227M 15.34B 230M 1.6B 620M 7.84B 599M 586M 25.17B EV / Sales 2026 *
-
EV / Sales 2027 * 160x
Free-Float
97.7%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Protara Therapeutics, Inc.

1 day-2.17%
1 week-17.68%
Current month-11.48%
1 month-31.47%
3 months-33.50%
6 months-47.16%
Current year-49.34%
1 week 2.62
Extreme 2.62
3.34
1 month 2.62
Extreme 2.62
4.02
Current year 2.62
Extreme 2.62
7.5
1 year 2.62
Extreme 2.62
7.82
3 years 1.04
Extreme 1.04
10.48
5 years 1.04
Extreme 1.04
10.48
10 years 1.04
Extreme 1.04
67.08
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 45 01/03/2019
Chief Executive Officer 54 01/11/2017
Director of Finance/CFO 58 30/01/2023
Director TitleAgeSince
Chairman 67 01/01/2020
Director/Board Member 68 01/01/2020
Director/Board Member 60 01/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/06/26 Don

Founder

-30,000 0.0534%
15/06/26 Free

Director

31,000 0.0552%
15/06/26 Free

Director

31,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%-17.68%-45.56%+64.14% 160M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+79.01% 57.39B
+0.89%-0.63%+2.17%+35.99% 47.64B
+0.36%+0.81%+342.39%+748.97% 44.29B
-0.96%-4.50%+24.96%+31.45% 42.5B
-0.20%-0.77%+4.13%+111.69% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+3.75%+31.90%+29.14% 28.53B
+0.05%-1.64%-8.14%-12.10% 24.34B
Average +0.00%-2.30%+43.07%+123.65% 39.07B
Weighted average by Cap. +0.43%-0.85%+57.10%+139.52%

Financials

2026 *2027 *
Net sales - 1M 888K 829K 756K 1.43M 96.13M 1.44M 10.04M 3.89M 49.14M 3.75M 3.67M 158M
Net income -85.87M -76.29M -71.21M -64.9M -122M -8.25B -124M -862M -334M -4.22B -322M -315M -13.54B -108M -95.81M -89.43M -81.51M -154M -10.37B -155M -1.08B -419M -5.3B -405M -396M -17.01B
Net Debt - -
Logo Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing transformative therapies for people with cancer and rare diseases. The Company's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.
Employees
46
Date Price Change Volume
02/10/26 $2.700 -2.17% 1,909,316
01/10/26 $2.760 -9.51% 4,999,036
30/09/26 $3.050 -4.98% 8,824,867
29/09/26 $3.210 -1.23% 391,465
28/09/26 $3.250 -0.91% 431,134
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.700USD
Average target price
25.71USD
Spread / Average Target
+852.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARA Stock